[1]曾倩琪,肖 瑶,谭 劲,等.扶正解毒方调理OSF癌症术后的临床效果观察[J].医学信息,2025,38(04):112-115.[doi:10.3969/j.issn.1006-1959.2025.04.019]
　ZENG Qianqi,XIAO Yao,TAN Jin,et al.Clinical Efficacy Observation of Fuzheng Jiedu Formula in Conditioning OSF Cancer After Surgery[J].Journal of Medical Information,2025,38(04):112-115.[doi:10.3969/j.issn.1006-1959.2025.04.019]
点击复制

扶正解毒方调理OSF癌症术后的临床效果观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年04期
页码:
112-115
栏目:
论著
出版日期:
2025-02-15

文章信息/Info

Title:
Clinical Efficacy Observation of Fuzheng Jiedu Formula in Conditioning OSF Cancer After Surgery
文章编号:
1006-1959（2025）04-0112-04
作者:
曾倩琪1; 肖 瑶1; 谭 劲2; 叶 瑶1
1.湖南中医药大学第一中医临床学院，湖南 长沙 410000；2.湖南中医药大学第一附属医院口腔科，湖南 长沙 410000
Author(s):
ZENG Qianqi1;  XIAO Yao1;  TAN Jin2;  YE Yao1
1.The First School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha 410000, Hunan, China; 2.Department of Stomatology, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410000, Hunan, China
关键词:
口腔黏膜下纤维化; 口腔癌术后; 扶正解毒方; 血清肿瘤标志物; 复发率
Keywords:
Oral submucous fibrosis;  Postoperative oral cancer;  Fuzheng jiedu formula;  Serum tumor markers;  Recurrence rate
分类号:
R739.8
DOI:
10.3969/j.issn.1006-1959.2025.04.019
文献标志码:
A
摘要:
目的 观察使用扶正解毒方对口腔黏膜下纤维化（OSF）癌症术后的调理康复效果。方法 选择2019年6月-10月就诊于湖南中医药大学第一附属医院的60例OSF癌症术后需中医药调理患者，按照随机数字表法分成两组，每组30例。对照组使用康艾扶正片治疗，治疗组使用扶正解毒方治疗，比较两组用药疗效、口腔病症评分、血清学肿瘤标志物（CEA、CA125）水平，以及5年复发率。结果 治疗组总有效率为90.00%，高于对照组的6.67%（P＜0.05）；两组治疗后口腔黏膜刺激痛、僵硬感、纤维条索、开口度口腔症状评分均低于治疗前，治疗组低于对照组（P＜0.05）；治疗组治疗后血清CEA浓度、CA125浓度均低于治疗前，差异有统计学意义（P＜0.05）；5年内两组均有复发病例，治疗组复发率为10.00%，低于对照组的20.00%。结论 扶正解毒方能改善OSF癌症术后口腔不适主症，促进机体康复；降低血清学肿瘤标志物水平，降低复发率。
Abstract:
Objective To observe the therapeutic effects of Fuzheng Jiedu Formula on postoperative recovery in patients with oral submucous fibrosis (OSF) cancer. Methods A total of 60 patients requiring traditional Chinese medicine conditioning for postoperative OSF cancer were selected from the First Affiliated Hospital of Hunan University of Chinese Medicine between June and October 2019. They were randomly divided into two groups using a random number table, with 30 patients in each group. The control group was treated with Kang′ai Fuzheng tablets, while the treatment group received Fuzheng Jiedu formula. The therapeutic efficacy, oral symptom scores, levels of serological tumor markers (CEA, CA125), and 5-year recurrence rates were compared between the two groups. Results The total effective rate in the treatment group was 90.00%, which was higher than 6.67% in the control group (P<0.05). After treatment, the scores for oral symptoms such as mucosal irritation pain, stiffness, fibrous cords, and mouth opening were lower in both groups than those before treatment, and those in the treatment group were lower than those in the control group (P<0.05). The serum levels of CEA and CA125 decreased in treatment groups after treatment, with statistically significant differences (P<0.05). Within 5 years, recurrence cases were observed in both groups, with a recurrence rate of 10.00% in the treatment group, which was lower than the 20.00% in the control group. Conclusion Fuzheng Jiedu formula can alleviate the main oral symptoms in patients after OSF cancer surgery, promote physical recovery, reduce the levels of serological tumor markers, and with lower recurrence rate.

参考文献/References:

[1]More CB,Rao NR.Proposed clinical definition for oral sumucous fibrosis[J].J Oral Biol Craniofac Res,2019,9(4):311-314.[2]Peng Q,Li H,Chen J,et al.Oral submucous fibrosis in Asian countries[J].J Oral Pathol Med,2020,49(4):294-304.[3]薛丽琼,郭晔.局部晚期口腔癌的新辅助治疗[J].中国肿瘤临床,2024,51(19):988-992.[4]何悦,祝奉硕,马春跃,等.晚期或复发性口腔(口咽)癌的救治性外科治疗中国专家共识[J].中国口腔颌面外科杂志,2024,22(6):521-528.[5]Rangaswamy S,Chikkalingaiah RG,Sanjeevarayappa PN,et al.Carcinoma Arising in the Background of Oral Submucous Fibrosis[J].Ann Maxillofac Surg,2019,9(2):247-252.[6]李江,张春叶.口腔癌及口咽癌病理诊断规范[J].中国口腔颌面外科杂志,2020,18(4):289-296.[7]李元聪,谭劲,文倩,等.口腔黏膜下纤维化中医临床诊疗方案[J].实用口腔医学杂志,2018,34(6):838-840.[8]朱可可,李元聪,谭劲.李元聪教授治疗口腔癌临证经验[J].湖南中医药大学学报,2021,41(9):1422-1426.[9]谭劲,李元聪,陈安,等.丹玄口康治疗口腔黏膜下纤维化的临床研究[J].湖南中医药大学学报,2006,26(5):41-43.[10]张杏羡.化学发光免疫法对肿瘤生物标志物的检验效果分析[J].医学信息,2022,35(20):154-156.[11]Zaman SU,Aqil S,Sulaiman MA.Predictors of locoregional recurrence in early stage buccal cancer with pathologically clear surgical margins and negative neck[J].Acta Otorrinolaringol Esp (Engl Ed),2018,69(4):226-230.[12]Pindborg JJ.Clinical relevance of precancerous lesions of oral mucosa[J].Recent Results Cancer Res,1994,134:9-16.[13]翦新春,高兴.口腔黏膜下纤维性变的病因、致病机理、诊断与治疗[J].口腔疾病防治,2021,29(4):217-225.[14]Dzebo S,Mahmutovic J,Erkocevic H.Quality of life of patients with oral cavity cancer[J].Mater Sociomed,2017,29(1):30-34.[15]张泽君,南欣荣,闫星泉.Ⅲ~Ⅳ期口腔癌患者术后复发的危险因素及复发患者的预后分析[J].医学研究杂志,2021,50(2):102-106.[16]吴西彩,夏向峰,徐德龙,等.血清肿瘤标志物联合检测在结肠癌诊断和预后评估中的价值[J].中国医药,2024,19(12):1806-1810.[17]魏晓玲.血清CA125,CEA,CA199与胃癌病理特征的相关性[J].西藏医药,2024,45(1):37-38.[18]邹剑,许蕾,王超.血清TPS、CEA及CA125对口腔癌的诊断价值分析[J].中国煤炭工业医学杂志,2022,25(5):539-543.[19]李蔚,蒋曼,王任炜,等.益气扶正解毒汤联合化疗对口腔癌术后患者免疫功能的影响[J].中国处方药,2022,20(4):145-147.[20]李娅玲，程宇航，薛莎.一贯煎合牵正散加减治疗口腔癌术后镜面舌、裂纹舌案例一则[J].光明中医,2019,34(5):699-700.[21]顾兵,孙松昌.腹腔镜切除术及益气扶正化瘀解毒汤对结肠癌的治疗效果[J].现代仪器与医疗,2021,27(3):29-31,42.

更新日期/Last Update: 1900-01-01